1 reported a study of genetic variation at a biallelic functional polymorphism located in the promoter region of the serotonin transporter gene (SLC6A4) and found a significant increase in the number of suicide victims, as compared to normal living subjects, who were carriers of at least one short allele. Their data indicate that 90% of suicide victims had at least one short allele and that one third of their controls had no such alleles. They also found that homozygotes for the long variants were significantly less frequent among suicide victims.
Suicide and the serotonin transporter gene
SIR -In a recent issue of this Journal, Bondy et al 1 reported a study of genetic variation at a biallelic functional polymorphism located in the promoter region of the serotonin transporter gene (SLC6A4) and found a significant increase in the number of suicide victims, as compared to normal living subjects, who were carriers of at least one short allele. Their data indicate that 90% of suicide victims had at least one short allele and that one third of their controls had no such alleles. They also found that homozygotes for the long variants were significantly less frequent among suicide victims.
Mounting evidence has suggested over the last years that a genetic component may increase the predisposition to suicide, 2 in which it appears that deficiencies of the serotonin system play a significant role. 3 The polymorphism located in the promoter region of SLC6A4 has been found to alter the transporter expression, and therefore, it is an interesting candidate gene for suicide. However, the association between suicidal behavior and the short variant of this locus seems counterintuitive, even though decreased serotonin transporter binding has been found in platelets from depressed subjects and in some postmortem brain studies of depression and suicide. 4 Indeed, the short allele is associated with decreased expression of the transporter in brain cells and platelets, 5 resulting in a reduction of serotonin uptake and consequent increase in serotonergic neurotransmission. In order to further explore this association, we investigated a relatively large sample of suicide completers, but failed to replicate the findings reported by Bondy et al. 1 The promoter polymorphism of the SLC6A4 gene was genotyped in a sample of 95 suicide completers who were consecutively recruited at the Montreal Central Morgue and compared to 120 healthy living controls of similar ethnic origin (French Canadians). Informed consent was obtained from all living subjects or from the next of kin for completers. Allelic and genotypic distributions are presented in Table 1 . In our Molecular Psychiatry sample, we did not observe an increased frequency of the short allele or of genotypes containing one or two copies of the short allele among suicide completers. In fact, suicide cases had a larger proportion of the long, rather than the short allele. However, the differences were not statistically significant ( 2 = 2.82, df = 1, P = 0.09).
In summary, we were unable to replicate the findings reported by Bondy et al. 1 The discrepancies between our studies may be related to differences in sample composition.
Different diagnostic distributions between samples could lead to different results if SLC6A4 is not associated with suicidal behavior but rather with one of the psychiatric diagnoses which are prevalent among suicide completers. It is difficult to assess the relevance of this issue, as Bondy et al did not report information on psychiatric diagnoses in their suicide cases. For instance, one possibility could be a large proportion of subjects with anxiety-related traits. Indeed, this could account not only for their positive result but also for the allele (short) associated, as it would be consistent with previous findings. 5, 6 In our sample, prevalence rates are similar to our previous studies, 7 as well as to other reports published in the literature, 8 and indicate a small fraction of subjects with anxiety disorders (10.8%). Another possible explanation for the inconsistent findings is the origin of our sample, which was drawn from an isolated population with a well-documented founder effect. 9, 10 Genetic heterogeneity is often thought to account for a large population of non-replications in psychiatric genetics. Finally, type II error could also explain our negative association. Although possible, this is unlikely given that our study had almost twice the number of suicide completers included in the Bondy et al study. Moreover, although two association studies in attempters reported positive results with the short allele, 11, 12 the results from two other studies in suicide completers, one in a small sample of depressed victims, in which an increased frequency of the long allele was observed 13 and a recent publication in a sample of 82 completers 14 
